Tough US market deals Mylan second quarter blow

8 August 2018
biosimilars_samples_large

Generic and specialty pharmaceuticals firm Mylan (Nasdaq: MYL) has announced lower than expected second quarter 2018 revenues of $2.81 billion, down 5% compared to the prior year period.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share figure was $0.07, down 87% from 2017.

Analysts had forecast sales of around $2.96 billion, according to the Financial Times. Ahead of the opening bell in New York, shares in the firm were trading almost 5% lower than the previous close.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars